SCHEMBL14728242

SCHEMBL14728242

O=C1c2ccccc2C(=O)N1c1nn2c(O)cc(O)nc2c1Cc1cccc2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 2/20 0.38
POLB P06746 1/20 0.38
CMA1 P23946 3/20 0.36
IDH1 O75874 1/20 0.35
ALDH1A1 P00352 3/20 0.34
CA12 O43570 1/20 0.34
CETP P11597 1/20 0.34
TYMP P19971 1/20 0.34
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
GLA P06280 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728511 0.82 POLB (0.39) NQO1POLBCMA1IDH1ALDH1A1
SCHEMBL14728400 0.79 SRC (0.39) NQO1CMA1IDH1ALDH1A1CETP
SCHEMBL14720276 0.68 POLB (0.37) NQO1POLBCMA1ALDH1A1CA12
SCHEMBL14720260 0.65 PIK3CB (0.42) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL11747294 0.63 ESR1 (0.35) ALDH1A1MEN1MAPTHPGDKMT2A
SCHEMBL2116159 0.63 ADRA2A (0.45) NQO1CETPMAPTMAPK1
SCHEMBL14720198 0.63 PIK3CB (0.54) MAPTPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL14723087 0.63 PIK3CB (0.58) MAPTPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL14720170 0.61 ALDH1A1 (0.39) NQO1IDH1ALDH1A1CETPMEN1
SCHEMBL1337353 0.60 CA12 (0.57) POLBALDH1A1CA12MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
WO-2013028263-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CA, PI4K2B NQO1 4033/4885POLB 910/4885CMA1 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.